肾脏疾病患者的癌症风险与死亡率:一项基于人群的队列研究
该研究纳入加拿大安大略省2007至2016年有估算肾小球滤过率数据的成人、接受维持性透析者及肾移植受者,评估各期慢性肾脏病(CKD)的癌症发病与死亡风险。结果显示轻中度CKD和肾移植受者癌症风险升高,晚期CKD未见升高,但CKD患者癌症特异性死亡风险显著更高。
要点
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,CKD G3a期癌症诊断风险升高(AHR 1.08),G4、G5期降低(AHR 0.85、0.81)。
- 肾移植受者癌症诊断风险升高(AHR 1.25),接受透析者未见升高(AHR 1.01)。
- CKD G3a、G3b、G4期及肾移植受者癌症特异性死亡风险均升高,以膀胱癌、肾癌和多发性骨髓瘤尤为突出。
核心结论
- 肾脏疾病背景下癌症发病数可观;轻中度CKD和肾移植受者癌症风险升高,晚期肾脏病未见升高;肾脏病患者癌症相关死亡率显著更高,尤其是泌尿系统癌症和骨髓瘤;作者认为需要在CKD人群中制定检出和管理这些癌症的策略。
研究设计与样本
- 基于人群的队列研究,纳入2007至2016年加拿大安大略省全部有估算肾小球滤过率数据的成人居民,以及接受维持性透析或已接受肾移植者。
- 分析纳入5,882,388名有估算肾小球滤过率数据者、29,809名接受透析者和4,951名肾移植受者。
- 按首次具有2次估算肾小球滤过率评估的日期,或登记接受维持性透析、接受肾移植的日期分组。
- 估算肾小球滤过率分为≥60、45-59、30-44、15-29和<15 mL/min/1.73 m2,后4组分别对应KDIGO CKD G3a、G3b、G4、G5期。
- 采用Fine和Gray子分布风险模型分析。
主要发现
- 肾脏病患者癌症累积发病率在10.8%至15.3%之间。
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,CKD G3a、G3b、G4、G5期癌症诊断的校正风险比分别为1.08(95%CI 1.07-1.10)、0.99(95%CI 0.97-1.01)、0.85(95%CI 0.81-0.88)、0.81(95%CI 0.73-0.90)。
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,接受透析者和肾移植受者癌症诊断的校正风险比分别为1.01(95%CI 0.96-1.07)和1.25(95%CI 1.12-1.39)。
- 肾脏病患者诊断时4期癌症比例更高。
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,CKD G3a、G3b、G4期和肾移植受者癌症特异性死亡风险的校正风险比分别为1.27(95%CI 1.23-1.32)、1.29(95%CI 1.24-1.35)、1.25(95%CI 1.18-1.33)和1.48(95%CI 1.18-1.87)。
关键数值与推荐
- 估算肾小球滤过率分组为≥60、45-59、30-44、15-29和<15 mL/min/1.73 m2,后4组分别对应KDIGO CKD G3a、G3b、G4、G5期。
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,CKD G3a期癌症诊断AHR为1.08(95%CI 1.07-1.10),G3b期为0.99(95%CI 0.97-1.01)。
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,CKD G4期癌症诊断AHR为0.85(95%CI 0.81-0.88),G5期为0.81(95%CI 0.73-0.90)。
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,透析者癌症诊断AHR为1.01(95%CI 0.96-1.07),肾移植受者为1.25(95%CI 1.12-1.39)。
- 与估算肾小球滤过率≥60 mL/min/1.73 m2者相比,CKD G3a、G3b、G4期和肾移植受者癌症特异性死亡AHR分别为1.27(95%CI 1.23-1.32)、1.29(95%CI 1.24-1.35)、1.25(95%CI 1.18-1.33)和1.48(95%CI 1.18-1.87)。
临床怎么用
- 作者认为需要在CKD人群中制定检出和管理这些癌症的策略。
局限性
- 可能存在未测量的混杂因素。
- 推断因果关系的能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Patients with chronic kidney disease (CKD) may be at increased risk for cancer. CKD may also be associated with worse cancer outcomes. This study examined cancer incidence and mortality across the spectrum of CKD. STUDY DESIGN: Population-based cohort study. SETTING & PARTICIPANTS: All adult Ontario residents with data on estimated glomerular filtration rate (eGFR) or who were receiving maintenance dialysis or had received a kidney transplant (2007-2016). EXPOSURE: Patients were categorized as of the first date they had 2 eGFR assessments or were registered as receiving maintenance dialysis or having received a kidney transplant. eGFR levels were further categorized as ≥60, 45-59, 30-44, 15-29, and <15 mL/min/1.73 m2; the latter 4 groups are consistent with KDIGO (Kidney Disease: Improving Global Outcomes) CKD categories G3a, G3b, G4, and G5, respectively. OUTCOMES: Overall and site-specific cancer incidence and mortality. ANALYTICAL APPROACH: Fine and Gray subdistribution hazard models. RESULTS: Among 5,882,388 individuals with eGFR data, 29,809 receiving dialysis, and 4,951 having received a kidney transplant, there were 325,895 cancer diagnoses made during 29,993,847 person-years of follow-up. The cumulative incidence of cancer ranged between 10.8% and 15.3% in patients with kidney disease. Compared with patients with eGFR ≥60 mL/min/1.73 m2, adjusted hazard ratios (AHRs) for a cancer diagnosis among patients with CKD G3a, G3b, G4, and G5 were 1.08 (95% CI, 1.07-1.10), 0.99 (95% CI, 0.97-1.01), 0.85 (95% CI, 0.81-0.88), and 0.81 (95% CI, 0.73-0.90), respectively. The AHRs for patients receiving dialysis and who had received a transplant were 1.01 (95% CI, 0.96-1.07) and 1.25 (95% CI, 1.12-1.39), respectively. Patients with kidney disease had higher proportions of stage 4 cancers at diagnosis. Patients with CKD G3a, G3b, and G4 and transplant recipients had increased risks of cancer-specific mortality (AHRs of 1.27 [95% CI, 1.23-1.32], 1.29 [95% CI, 1.24-1.35], 1.25 [95% CI, 1.18-1.33], and 1.48 [95% CI, 1.18-1.87], respectively). The risks of bladder and kidney cancers and multiple myeloma were particularly increased in CKD, and mortality from these malignancies increased with worsening kidney function. LIMITATIONS: Possible unmeasured confounding and limited ability to infer causal associations. CONCLUSIONS: Cancer incidence in the setting of kidney disease is substantial. Cancer risk was increased in mild to moderate CKD and among transplant recipients, but not in advanced kidney disease. Cancer-related mortality was significantly higher among patients with kidney disease, particularly urologic cancers and myeloma. Strategies to detect and manage these cancers in the CKD population are needed.
引用
- Kitchlu A, Reid J, Jeyakumar N, et al. Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study. Am J Kidney Dis. 2022. PMID: 35405208. doi:10.1053/j.ajkd.2022.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。